Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2025)

Historic Gross Margin for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to 61.7%.

  • Collegium Pharmaceutical's Gross Margin rose 9400.0% to 61.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.22%, marking a year-over-year decrease of 51400.0%. This contributed to the annual value of 59.76% for FY2024, which is 22100.0% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Gross Margin stood at 61.7%, which was up 9400.0% from 57.65% recorded in Q2 2025.
  • Collegium Pharmaceutical's Gross Margin's 5-year high stood at 63.38% during Q1 2021, with a 5-year trough of 4.87% in Q4 2021.
  • In the last 5 years, Collegium Pharmaceutical's Gross Margin had a median value of 57.9% in 2022 and averaged 53.0%.
  • In the last 5 years, Collegium Pharmaceutical's Gross Margin tumbled by -629400bps in 2021 and then skyrocketed by 432800bps in 2022.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Gross Margin stood at 4.87% in 2021, then skyrocketed by 888bps to 38.41% in 2022, then skyrocketed by 65bps to 63.19% in 2023, then decreased by -15bps to 54.02% in 2024, then increased by 14bps to 61.7% in 2025.
  • Its Gross Margin stands at 61.7% for Q3 2025, versus 57.65% for Q2 2025 and 54.75% for Q1 2025.